Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.

Anisimov VN, Khavinson VK, Provinciali M, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Imyanitov EN, Mancini R, Franceschi C

International journal of cancer1 Sept 2002Cited by 22 (Europe PMC)

PMID12209581DOI10.1002/ijc.10570PepBankPUB-12209581

Publisher page PubMedAsk about this study

Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epitalon reduced the cumulative number of mammary tumors compared with saline.
In plain wordsIn mice prone to breast tumors, Epitalon reduced the total number of tumors compared with saline.
Peptide
Epitalon
Outcome
DecreaseCumulative number of mammary tumors
Study
mousen: not reported in source
HER-2/neu transgenic mice
Comparator
Saline
Outcome group
Tumor growth · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Source sentences
Summary
Epitalon treatment reduced the cumulative number and the maximum size of tumors (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958101
02AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epitalon reduced the maximum size of tumors compared with saline.
In plain wordsIn mice prone to breast tumors, Epitalon reduced the largest tumor size compared with saline.
Peptide
Epitalon
Outcome
DecreaseMaximum tumor size
Study
mousen: not reported in source
HER-2/neu transgenic mice
Comparator
Saline
Outcome group
Tumor growth · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Source sentences
Summary
Epitalon treatment reduced the cumulative number and the maximum size of tumors (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958102
03AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, more Epitalon-treated mice bore only one mammary tumor than saline-treated mice.
In plain wordsIn mice prone to breast tumors, more Epitalon-treated mice had only one tumor than saline-treated mice.
Peptide
Epitalon
Outcome
IncreaseMice bearing one mammary tumor
Study
mousen: not reported in source
HER-2/neu transgenic mice
Comparator
Saline
Outcome group
Tumor growth · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Source sentences
Summary
Furthermore, the number of mice bearing 1 mammary tumor was increased, whereas the number of mice bearing 2 or more mammary tumors was reduced in Epitalon-treated in comparison to saline-treated animals (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958103
04AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, fewer Epitalon-treated mice bore 2 or more mammary tumors than saline-treated mice.
In plain wordsIn mice prone to breast tumors, fewer Epitalon-treated mice had two or more tumors than saline-treated mice.
Peptide
Epitalon
Outcome
DecreaseMice bearing two or more mammary tumors
Study
mousen: not reported in source
HER-2/neu transgenic mice
Comparator
Saline
Outcome group
Tumor growth · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Source sentences
Summary
Furthermore, the number of mice bearing 1 mammary tumor was increased, whereas the number of mice bearing 2 or more mammary tumors was reduced in Epitalon-treated in comparison to saline-treated animals (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958104
05AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epitalon reduced the size of lung metastases compared with saline.
In plain wordsIn mice prone to breast tumors, Epitalon reduced the size of lung metastases compared with saline.
Peptide
Epitalon
Outcome
DecreaseSize of lung metastases
Study
mousen: not reported in source
HER-2/neu transgenic mice
Comparator
Saline
Outcome group
Tumor growth · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Source sentences
Summary
The size but not the number of lung metastases was reduced in Epitalon-treated compared to saline-treated mice (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958105
06AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epitalon did not reduce the number of lung metastases compared with saline.
In plain wordsIn mice prone to breast tumors, Epitalon did not change the number of lung metastases compared with saline.
Peptide
Epitalon
Outcome
No significant changeNumber of lung metastases
Study
mousen: not reported in source
HER-2/neu transgenic mice
Comparator
Saline
Outcome group
Tumor growth · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Source sentences
Summary
The size but not the number of lung metastases was reduced in Epitalon-treated compared to saline-treated mice (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958106
07AnimalAnimal study (in vivo)Mechanism
In HER-2/neu transgenic mice, Epitalon lowered HER-2/neu mRNA expression in mammary tumors 3.7-fold compared with controls.
In plain wordsIn mice prone to breast tumors, Epitalon lowered tumor HER-2/neu gene activity compared with controls.
Peptide
Epitalon
Outcome
DecreaseHER-2/neu mRNA expression in mammary tumors
Study
mousen: not reported in source
HER-2/neu transgenic mice
Comparator
Saline
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Measurements
HER-2/neu mRNA reduction
3.7 fold
Epitalon vs control
Source sentences
Summary
A 3.7-fold reduction in the expression of HER-2/neu mRNA was found in mammary tumors from HER-2/neu transgenic mice treated with Epitalon compared to control animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958107
08AnimalAnimal study (in vivo)Mechanism
In HER-2/neu transgenic mice, HER-2/neu mRNA expression in tumors was lower with Epitalon than with Vilon.
In plain wordsIn mice prone to breast tumors, tumor HER-2/neu gene activity was lower with Epitalon than with Vilon.
Peptide
Epitalon
Outcome
DecreaseHER-2/neu mRNA expression, Epitalon versus Vilon
Study
mousen: not reported in source
HER-2/neu transgenic mice
Comparator
Vilon
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Measurements
HER-2/neu mRNA, Vilon vs Epitalon
1.9 fold
higher in Vilon
Source sentences
Summary
The expression of mRNA for HER-2/neu was also partially reduced in Vilon-treated mice, but it remained significantly higher in Vilon- than in Epitalon-treated animals (1.9-fold increase).
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958108
09AnimalAnimal study (in vivo)Safety outcome
In HER-2/neu transgenic mice, Vilon increased mammary cancer incidence versus control (p < 0.05).
In plain wordsIn mice, Vilon increased mammary cancer incidence compared with control.
Peptide
Vilon (KE)
Outcome
IncreaseMammary cancer incidence
Study
mousen: not reported in source
Female FVB/N HER-2/neu transgenic mice
Comparator
Saline control
Outcome group
Tumor growth · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Source sentences
Summary
The treatment with Vilon produced significant negative effects when compared to the control group, with an increased incidence of mammary cancer development (p < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958109
10AnimalAnimal study (in vivo)Safety outcome
In HER-2/neu transgenic mice, Vilon shortened the mean tumor latent period versus control (p < 0.05).
In plain wordsIn mice, tumors appeared sooner on average with Vilon than control.
Peptide
Vilon (KE)
Outcome
DecreaseMean tumor latent period
Study
mousen: not reported in source
Female FVB/N HER-2/neu transgenic mice
Comparator
Saline control
Outcome group
Tumor growth · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Source sentences
Summary
The treatment with Vilon produced significant negative effects when compared to the control group, with an increased incidence of mammary cancer development (p < 0.05), a shorter mean latent period of tumors (p < 0.05) and an increased cumulative number of tumors (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958110
11AnimalAnimal study (in vivo)Safety outcome
In HER-2/neu transgenic mice, Vilon increased the cumulative number of tumors versus control (p < 0.05).
In plain wordsIn mice, Vilon increased the total tumor count compared with control.
Peptide
Vilon (KE)
Outcome
IncreaseCumulative tumor number
Study
mousen: not reported in source
Female FVB/N HER-2/neu transgenic mice
Comparator
Saline control
Outcome group
Tumor growth · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Source sentences
Summary
The treatment with Vilon produced significant negative effects when compared to the control group, with an increased incidence of mammary cancer development (p < 0.05), a shorter mean latent period of tumors (p < 0.05) and an increased cumulative number of tumors (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958111
12AnimalAnimal study (in vivo)Mechanism
In HER-2/neu transgenic mice, Vilon partially reduced HER-2/neu mRNA expression in mammary tumors versus control.
In plain wordsIn mice, Vilon partly reduced HER-2/neu gene expression in mammary tumors compared with control.
Peptide
Vilon (KE)
Outcome
DecreaseHER-2/neu mRNA expression
Study
mousen: not reported in source
Female FVB/N HER-2/neu transgenic mice
Comparator
Saline control
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Source sentences
Summary
The expression of mRNA for HER-2/neu was also partially reduced in Vilon-treated mice, but it remained significantly higher in Vilon- than in Epitalon-treated animals (1.9-fold increase).
2 context sentences(design, population, supporting numbers)
Summary · context
A 3.7-fold reduction in the expression of HER-2/neu mRNA was found in mammary tumors from HER-2/neu transgenic mice treated with Epitalon compared to control animals.
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958112
13AnimalAnimal study (in vivo)Mechanism
In transgenic mice, mammary tumor HER-2/neu mRNA expression remained significantly higher with Vilon than Epitalon, with a 1.9-fold increase.
In plain wordsIn mice, mammary tumor HER-2/neu gene expression was higher with Vilon than Epitalon.
Peptide
Vilon (KE)
Outcome
IncreaseHER-2/neu mRNA expression
Study
mousen: not reported in source
Female FVB/N HER-2/neu transgenic mice
Comparator
Epitalon
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
1 microg/mouse · subcutaneousAs given in this study (mouse).
Measurements
HER-2/neu mRNA expression
1.9 fold
Vilon versus Epitalon
Source sentences
Summary
The expression of mRNA for HER-2/neu was also partially reduced in Vilon-treated mice, but it remained significantly higher in Vilon- than in Epitalon-treated animals (1.9-fold increase).
1 context sentence(design, population, supporting numbers)
Summary · context
Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon(R) (Ala-Glu-Asp-Gly) or with the peptide Vilon(R) (Lys-Glu) in a single dose of 1 microg/mouse for 5 consecutive days every month.
Report a problemFND-1220958113

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 10Current
28 Oct 2026, 02:02 UTC
The same notice was added 7 times, first on 21 Oct 2026, 17:05 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 2
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.